Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04942301
Other study ID # SIM-1904-04-ENDO-101
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date July 30, 2021
Est. completion date October 15, 2022

Study information

Verified date June 2021
Source Jiangsu Simcere Pharmaceutical Co., Ltd.
Contact qingxia fan
Phone 13939039058
Email fqx2243@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is an open-label, randomized, multicenter study to explore Endostar in combination with standard platinum-based chemotherapy with different methods in patients with advanced/metastatic non-small cell lung cancer (NSCLC)


Description:

Patients in group A received a standard 21-day treatment cycle of platinum-containing two-drug chemotherapy and endurance treatment. Yep The first cycle of the degree of use is 7.5mg/m2/day intravenous infusion for 4 hours (referred to as the time window of 4h 20min From the 1st day to the 14th day (D1-14 Endo cycle 2-4 uses 105mg/m2/cycle From the first day, continuous intravenous pump injection for 72 hours (the set time window is 72h±2h.). Patients in group B received a standard 21-day treatment cycle of platinum-containing two-drug chemotherapy and endurance treatment. Yep The first cycle of the degree of use is 7.5mg/m2/day intravenous infusion for 4 hours (referred to as the time window is 4h±20min From the 1st day to the 14th day (D1-14 Endo cycle 2-4 is used 105mg/m2/cycle From the first day, continuous intravenous pump injection for 168 hours (set time window is 168h±2h). Endostar and chemotherapy drugs are used for 4 cycles. Research will Use RECIST 1.1 standard to evaluate in progress and after enrollment Efficacy assessment will be conducted every 6±1 weeks until the disease progresses, new anti-tumor therapy is started, and the study is withdrawn or At the end of the study, the serum of Endo will be collected in different expected ways to evaluate the pharmacokinetic characteristics; Adverse events were evaluated according to CTCAE5.0 standards. The start time of the test is The first fine was when the informed consent form was signed. The end of the test is the last The subject completed 24 weeks after the first treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 24
Est. completion date October 15, 2022
Est. primary completion date December 25, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Volunteer to participate in clinical trials and sign an informed consent form. - Age = 18 years old, including gender. - Advanced or metastatic NSCLC confirmed by histology and/or cytology: Have not received Systemic chemotherapy for advanced disease (Patients with sensitive mutations such as EGFR and ALK have received corresponding standard alternative treatments, But patients who have not received chemotherapy can be included in the group; have received single-agent PD-L 1 and other immune checkpoint inhibitors Patients, but patients who have not received chemotherapy can enter the group). - At least one measurable lesion (based on RECIST 1.1). - ECOG scores 0~1. - Expected survival time = 3 months. - The functions of major organs are basically normal, and the laboratory test values during the screening period meet the following standards: System Laboratory Inspection Standard hematology Absolute neutrophil count >1.5 ×109/L Platelet >100×109/L Hemoglobin >90g/L kidney Serum creatinine or Creatinine clearance rate (CrCl) or glomerular filtration rate (GFR) (Cockcroft-Gault formula) <1.5 × ULN or >60 mL/min1.73m2 (for patients with creatinine level = 1.5 × ULN) liver Total bilirubin (serum) <2.5 × ULN or Direct bilirubin <ULN (for patients with total bilirubin level = 1.5×ULN) AST and ALT <2.5 × ULN or =5 × ULN (for patients with liver metastases) Blood clotting International normalized ratio (INR) or prothrombin time (PT) <1.5 × ULN, unless the patient is receiving anticoagulation therapy Urine routine Urine protein =+ (For patients with urine protein =++, 24-hour urine protein quantification is required, and 24-hour urine protein needs to be less than 1g) · Women of childbearing age during the screening period had negative blood pregnancy test results. The patient agrees to self-sign and know Consent to use reliable contraceptive methods within 90 days after the end of treatment. Exclusion Criteria: - Patients with uncontrolled primary central nervous system tumors, brain metastases, or meningeal metastases. Patients who were asymptomatic or had their symptoms under treatment (stable and asymptomatic at least 4 weeks after treatment) were allowed to join the group. - Imaging (CT, PET-CT, or MRI) shows tumors invading large blood vessels. - It is first clear that pulmonary hemorrhage/hemoptysis (> 1/2 teaspoon about 2.5ml bright red blood) or other clinically significant bleeding symptoms or obvious bleeding possibility occurred in the first 3 months. - Severe uncontrollable hypertension (defined as systolic blood pressure> 150mmHg and/or diastolic blood pressure> 100mg, or accompanied by hypertensive crisis, hypertensive encephalopathy). - The QTcF interval of ECG> 480ms within 6 months before the first first time. - Severe infections within 4 weeks before the first administration require intravenous antibiotics or hospitalization. - Before the first dose, the adverse events caused by any intervention have not recovered to normal or =1 grade. Patients with alopecia (any grade) and sensory neuropathy (=2 grade) at both ends can be included in the group. - Received other major surgery besides diagnosis or biopsy within 4 weeks before the first definition. - 4 weeks or 5 half-lives before the first time (for investigational drugs with known half-lives) internally as a patient Received experimental drug treatment. - Previously received anti-angiogenic drug treatment. - Received systemic anti-tumor therapy within 4 weeks before the first dose, including chemotherapy, macromolecular targeting, immunotherapy, and endocrine therapy; within 2 weeks before the first dose or within 5 half-lives of the drug (whichever is longer) ) Receiving small-molecule targeted drug therapy; receiving Chinese/herbal medicine with anti-tumor indications within 2 weeks before the first dose. - Patients who have received adjuvant chemotherapy within 6 months before the first dose and the disease recurs within 6 months after the start of adjuvant therapy. - Obvious gastrointestinal bleeding (such as esophageal or gastric varices) or a clear bleeding tendency occurred within 4 weeks before the first dose. - Those who are allergic to any active or inactive ingredients of Endo or the combined chemotherapeutics. - Known acute or active hepatitis B, or chronic hepatitis C, or syphilis infection, or human immunodeficiency virus (HIV) infection. - Patients during pregnancy or lactation. - Take CYP2C8 substrates (such as repaglinide, rosiglitazone), CYP2C8 inhibitors (such as gemfibrozil), CYP2C8 inducers (such as rifampicin) within 14 days before using the test drug in the first cycle, CYP3A4 substrates (such as midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, triazolam), CYP3A4 inhibitors (such as a Zanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin), CYP3A4 inducer (Such as rifampicin, carbamazepine); - The researcher believes that the patient has any clinical or laboratory abnormalities or other reasons that are not suitable for participating in this clinical study.

Study Design


Intervention

Drug:
Endostar
This product combined with other combined chemotherapeutics is used to treat patients with stage III/IV NSCLC who are newly treated or relapsed
Device:
use the vein pump to pump drugs
During the first 14 days of the first cycle, the experimental drug was pumped daily with an intravenous pump. During cycles 2-4, subjects in group A were pumped with experimental drugs for 3 days and subjects in group B were pumped with experimental drugs for 7 days.
Combination Product:
combination therapy
Combination therapy with chemotherapy drugs was used

Locations

Country Name City State
China Lan Mu Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Simcere Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other The objective response rate (ORR) The investigator evaluated the objective response rate (ORR), based on the RECIST 1.1 standard through study completion, an average of 1 year
Other disease control rate (DCR) The investigator evaluated the disease control rate (DCR), based on the RECIST 1.1 standard through study completion, an average of 1 year
Other the progression-free survival The investigator evaluated the progression-free survival based on the RECIST 1.1 standard through study completion, an average of 1 year
Primary peak time (Tmax) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Primary peak concentration (Cmax) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Primary area under curve (AUC, Including AUC0-t, AUC0-8) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Primary terminal elimination half-life (T1/2) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Primary steady-state minimum blood concentration (CSS min) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Primary mean steady-state blood concentration (CSS AV) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Primary accumulation coefficient (RAC) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Primary mean residence time (MRT) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Primary apparent volume of distribution (VD) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Primary clearance rate (CL) pharmacokinetic parameters At the end of the second cycle, each cycle is 21 days
Secondary Adverse events (AE) incidence Adverse event (AE) incidence through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526691 - Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) Phase 1
Recruiting NCT05435248 - Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) Phase 1/Phase 2
Active, not recruiting NCT05941897 - A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy Phase 2
Recruiting NCT04612751 - Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03673332 - Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Phase 4
Completed NCT04177290 - A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients Phase 1